Type and results of reported outcomes
| Bisogno et al16 | Pramanik et al17 | Senerchia et al18 | |
| Extractions from articles | |||
| Overall survival | HR 0.52 (95% CI 0.32 to 0.86) p=0.0097 | HR 0.74 (95% CI 0.50 to 1.09) p=0.13 | HR 0.9 (95% CI n.r.) p=0.9 |
| Overall survival other than bone sarcoma | HR 0.52 (95% CI 0.32 to 0.86) p=0.0097 | HR 0.43 (95% CI n.r.) p=0.02 | n.r. |
| Disease-free survival | HR 0.68 (95% CI 0.45 to 1.02) p=0.061 | n.r. | n.r. |
| Progression-free survival | n.r. | HR 0.69 (95% CI 0.47 to 1.03) p=0.07 | n.r. |
| Progression-free survival other than bone sarcoma | n.r. | HR 0.39 (95% CI: 0.18 to 0.81) p=0.01 | n.r. |
| Event-free survival | n.r. | n.r. | HR 1.2 (95% CI n.r.) p=0.4 |
| PedsQL Cancer Module: child, mean total score (SD)* | n.r. | −1.9 (20.22) vs −1.3 (22.92), p=0.87 | n.r. |
| PedsQL Cancer Module: parent, mean total score (SD)* | n.r. | 0.2 (20.81) vs −4.2 (20.51), p=0.33 | n.r. |
| Death | 13% (24 of 182) vs 22% (42 of 185) | n.r. | n.r. |
| Treatment-related mortality | n.r. | 0 | 3% (4 of 139) vs 2% (3 of 157) |
| Neutropenia, grade 3 to 4 | 81% (148 of 181) | 10% (6 of 56) vs 0% | n.r. |
| Neurology adverse events, grade 3 to 4 | 2% (3 of 181) | 0% vs 0% | n.r. |
| Nephrotoxicity, grade 3 to 4 | 1% (1 of 181) | 0% vs 0% | n.r. |
| Re-enacted data | |||
| Overall survival | HR 0.55 (95% CI 0.34 to 0.90) | HR 0.82 (95% CI 0.55 to 1.21) | HR 0.91 (95% CI 0.52 to 1.61) |
| Overall survival other than bone sarcoma | HR 0.55 (95% CI 0.34 to 0.90) | HR 0.58 (95% CI 0.29 to 1.15) | n.r. |
*PedsQL Cancer Module: results extracted from the associated study by Pramanik et al.19
ID, identifier; n.r., not reported; PedsQL Cancer Module, Paediatric Quality of Life Inventory in paediatric cancer version 3.